Body Surface Area (BSA): Formulas, Clinical Uses & What Your Result Means

What Is Body Surface Area?

Body surface area (BSA) is the total external surface area of the human body, expressed in square metres (m²). Unlike body weight, BSA scales better with organ size — kidneys, liver, and cardiac output all correlate more closely with BSA than with weight — which is why it is the preferred metric for dosing many cytotoxic drugs, normalising cardiac output measurements, and correcting glomerular filtration rate (GFR).

The Five Major BSA Formulas

No single BSA formula is universally agreed upon. Each was derived from a different population using different measurement techniques, so results vary slightly between them. The most widely used formulas are:

Normal BSA Values by Age and Sex

The average BSA for an adult male is approximately 1.9 m² and for an adult female approximately 1.6 m². These are averages, not targets — BSA is a measurement tool, not a health indicator like BMI. The reference value of 1.73 m² is used in medicine to normalise physiological parameters (e.g., GFR is reported as mL/min/1.73 m²).

Clinical Applications of BSA

Chemotherapy Dosing: Why BSA Became the Standard

BSA-based dosing for cytotoxic drugs traces back to Pinkel's 1958 observation that anticancer agents tolerated in adults could be safely scaled to children using surface area rather than weight. Today, the great majority of cytotoxic protocols still express doses in mg/m², including doxorubicin (60 mg/m²), paclitaxel (175 mg/m²), 5-fluorouracil, cyclophosphamide, and many targeted agents. The Mosteller formula is widely used in modern oncology because it produces results within about 2% of Du Bois in normal adults and requires only a pocket calculator. Many institutional protocols specify Mosteller, although ASCO considers any of the standard BSA formulas acceptable.

Cardiac Index and Haemodynamic Monitoring

Cardiac output (CO, L/min) measured by thermodilution, echocardiography, or non-invasive bioimpedance is divided by BSA to yield cardiac index (CI, L/min/m²). This normalisation lets clinicians compare haemodynamic status across patients of very different sizes. Reference ranges: a CI of about 2.5–4.0 L/min/m² is normal; values below about 2.2 L/min/m² (1.8 without support) are used in definitions of cardiogenic shock. Stroke volume index (SVI) and systemic vascular resistance index (SVRI) are similarly normalised. The Du Bois formula has been the historical reference in adult haemodynamics; many invasive monitors hardcode it.

GFR Correction and Kidney Function

Estimated GFR (eGFR) from CKD-EPI and MDRD equations is reported in mL/min/1.73 m² — that is, indexed to a standard adult BSA of 1.73 m², a value taken from average adult measurements published in the 1920s. This normalisation lets a 1.5 m² and a 2.1 m² patient be compared on the same CKD staging chart. For drug dosing, however, the absolute (de-indexed) CrCl matters: a 75 kg woman with BSA 1.65 m² and an eGFR of 30 mL/min/1.73 m² actually clears ~28.6 mL/min of drug. KDIGO guidance recommends using non-indexed eGFR (mL/min) to dose renally cleared drugs in patients at the extremes of body size.

Paediatric BSA: Why Haycock Is Different

The Du Bois 1916 derivation used 9 subjects, only one of whom was a child. The Mosteller, Gehan-George and Boyd formulas similarly underrepresent infants. The Haycock formula (PMID 650346, 1978) was specifically validated against direct geometric measurements in 81 subjects spanning neonates through adults, with particular accuracy below 30 kg. In paediatric oncology — where dosing errors translate directly to toxicity or undertreatment — Haycock is often preferred, although each protocol specifies its own formula. In Haycock's own data, the Du Bois formula increasingly underestimated BSA below 0.7 m², by about 8% in newborns — a clinically meaningful gap when dosing methotrexate or busulfan.

Obesity, Cachexia, and the Limits of BSA

BSA-based dosing assumes a roughly linear relationship between body size, organ mass and drug clearance. This breaks down at the extremes. Verbraecken et al. (Metabolism 2006, PMID 16546483) compared BSA formulas in 1,868 adults across normal weight, overweight and obese categories and found that Du Bois underestimated BSA in obese patients by about 3% in men and 5% in women. Clinically: capping chemotherapy doses at a fixed BSA (often 2.0 or 2.2 m²) has been common practice but is now discouraged for most cytotoxics, especially when treatment is given with curative intent, because under-dosing obese patients reduces tumour response. ASCO 2021 guidance explicitly recommends using actual body weight for BSA-based chemotherapy in adults with obesity unless toxicity warrants otherwise. Conversely, in cachexia (sarcopenic body composition with low muscle mass but preserved skin envelope), BSA may overestimate clearance and lead to toxicity.

Action Plan: Which BSA to Use by Context

Which Formula Should I Use?

For most adults, Du Bois and Mosteller produce similar results (within 2–3%). Mosteller is preferred for quick calculations and is used by many protocols. Haycock is the standard for paediatric patients. At the extremes of body size the formulas diverge more, so the formula named in the protocol matters. Always follow the formula specified in the clinical protocol or drug prescribing information.

Use the CalcVita Body Surface Area Calculator to compute your BSA instantly using all five validated formulas — Du Bois, Mosteller, Haycock, Gehan-George, and Boyd — with support for metric (cm/kg) and imperial (ft/lb) units.